linjc16/ctgov huggingface dataset:
Video Laryngoscope, New Intubation Device

Study Overview
=================
Brief Summary
-----------------
new glidoscope was tested on 401 patients

Detailed Description
-----------------
Four hundred and one patients who were scheduled for elective operation, were randomly assigned to be intubated by direct laryngoscopy using a Macintosh blade size 3rd (DL, n=196) or intubation using the video laryngoscope (VL, n=205). Prior to intubation all patients were given a similar regimen of induction of anesthesia. The patients were then intubated, using direct laryngoscopy or the VL, by a different anesthetist during which the larynx was inspected and given a laryngoscopy score. Time to intubate, failure rate, injuries, personnel pleasure and, aspiration rate were measured

Official Title
-----------------
Advanced Video Laryngoscope, a New Practical Intubation Device: Randomized Clinical Trial in 401 Patients

Conditions
-----------------
Elective Intubation

Intervention / Treatment
-----------------
* Device: video laryngoscope
* Device: traditional laryngoscope


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: elective operation who filled the consent Exclusion Criteria: poor intubation emergency cases hemodynamic derangement

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 68 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: videolaryngoscope group<br>video laryngoscopy was done for them | Device: video laryngoscope<br>* newly developed innovatory device<br>* Other names: glidescope;|
| Placebo Comparator: traditional laryngoscope<br>comparison to active group with routine laryngoscope | Device: traditional laryngoscope<br>* traditional way for intubation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| laryngoscopy grade | grade of laryngoscopy | hospital stay (average 48 hours) | 
| time to intubation | time to successful intubation in minutes | 60 minutes | 
| unsuccessful attempts | number of failure | 60 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| aspiration | clinical aspiration or radiological | hospital stay ( 48 hours) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Equipment, Laryngoscopy, Video Laryngoscope
Risk Factors for Cytomegalovirus Disease in Solid Organ Transplantation

Study Overview
=================
Brief Summary
-----------------
This study will investigate the clinical variables that may be used to predict who among the solid organ transplant recipients will develop cytomegalovirus (CMV) disease after completing antiviral prophylaxis.

Detailed Description
-----------------
This study will investigate the clinical and laboratory variables that may be used to predict who among the solid organ transplant recipients will develop CMV disease after completing antiviral prophylaxis. This is a retrospective study of patients seen at the Mayo Clinic during the past five years.

Official Title
-----------------
Clinical Predictors of Late-onset CMV Disease in Solid Organ Transplant Recipients: A Strategy to Improve the Benefits and Reduce the Risks of Anti-CMV Prophylaxis

Conditions
-----------------
Transplantation, Infection, Cytomegalovirus Infections

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Recipients of liver, kidney, pancreas, heart or lung transplantation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cytomegalovirus
A Study to Implement and Evaluate REFLECT Communication Curriculum for Oncology Based Medical Graduate Students

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to collect data from quarterly workshops (standardized patient simulations, reflective narratives, questionnaires, surveys, standardized patient and peer feedback, and participant critiques) of participants enrolled in oncology-based residencies and fellowships will be collected. The information that is gathered from this study will be used to describe this population that participate in the workshop and see whether or not introduction of a communication curriculum alongside with the training program will improve communication, self-awareness, and interpersonal skills over time.

Official Title
-----------------
Implementation and Prospective Evaluation of the REFLECT Communication Curriculum for Oncology Based Medical Graduate Students

Conditions
-----------------
Medical Trainees in Oncology Programs

Intervention / Treatment
-----------------
* Other: REFLECT Curriculum


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects: Resident or Fellow enrolled in an oncology related training program (Radiation Oncology, Medical Oncology, Palliative Medicine and Hospice Care, Neurooncology). Location: Mayo Clinic Arizona. Interest: Willingness to participate. Exclusion Criteria: Schedule does not permit to participation. Not enrolled in an oncology-based residency or fellowship at Mayo Clinic Arizona. Interest: Not willing to participate.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control Group<br>Standard oncology curriculum for medical trainees in oncology programs. | |
| Experimental: Reflective Group<br>Standard oncology curriculum with standardized patient simulation, in addition to the REFLECT Curriculum workshops for medical trainees in oncology programs. | Other: REFLECT Curriculum<br>* Annual quarterly workshops will consist of guest lecturers, role playing, patient panels, coaching, knowledge assessments, Standardized Patient (SP) simulations and debriefing/feedback sessions.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Emotional Intelligence | Change in emotional intelligence comparing baseline scores on the ESCI (Emotional and Social Competence Inventory) with scores on annual ESCI reassessments. | Baseline, annually through study completion approximately 10 years |
A Single-dose, Comparative Bioavailability Study of Two Formulations of Ursodiol 500mg Tablets Under Fed Conditions

Study Overview
=================
Brief Summary
-----------------
single-dose, comparative bioavailability study of two formulations of ursodiol 500mg tablets under fed conditions

Detailed Description
-----------------
A single-dose, comparative bioavailability study of two formulations of ursodiol 500mg tablets under fed conditions: open label, single-dose, randomized, two-period, two-treatment, two-sequence, crossover, comparative bioavailability study

Official Title
-----------------
A Single-dose, Comparative Bioavailability Study of Two Formulations of Ursodiol 500mg Tablets Under Fed Conditions

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Ursodiol 500 MG
* Drug: Urso Forte 500Mg Tablet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy, non-smoking, male and female subjects, 18 years of age or older BMI ≥ 19.0 and ≤ 30.0 kg/m2. Females who participate in this study will be of chilbearing or nonchildbearing potential Exclusion Criteria: • Known history or presence of clinically significant neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, genitourinary, psychiatric, or cardiovascular disease or any other condition which, in the opinion of the investigator, would jeopardized the safety of the subject or impact the validity of the study results

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ursodiol 500mg tablets<br>Ursodiol 500mg tablets followed by Urso Forte 500mg tablets | Drug: Ursodiol 500 MG<br>* Ursodiol 500mg tablets followed by Urso Forte 500mg tablets<br>|
| Active Comparator: Urso Forte 500mg tablets<br>Urso forte 500mg tablets followed by Ursodiol 500mg tablets | Drug: Urso Forte 500Mg Tablet<br>* Urso forte 500mg tablets followed by Ursodiol 500mg tablets<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maximum Plasma Concentration (Cmax) |  | 0-72hours | 
| Area under the plasma concentration versus time curve (AUC) |  | 0-72hours |
Long Term Study With B2036-PEG

Study Overview
=================
Brief Summary
-----------------
Primary objective: To investigate the efficacy and safety of Pegvisomant in Japanese patients with acromegaly.

Official Title
-----------------
Long-Term Study of B2036-PEG in Acromegaly - Long Term Study With B2036-PEG -

Conditions
-----------------
Acromegaly

Intervention / Treatment
-----------------
* Drug: Pegvisomant


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with acromegaly who have received at least one dose of B2036-PEG in the preceding study (A6291009). Exclusion Criteria: Switching to other therapeutic methods for acromegaly

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Pegvisomant|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the safety and efficacy of long-term B2036-PEG therapy in patients with acromegaly |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PK/PD evaluation |  |  |
Urology Database for Outcomes Research

Study Overview
=================
Brief Summary
-----------------
The purpose of initiating the urology database is to collect relevant retrospective data via chart review related to patients undergoing radical prostatectomy via the retropubic, perineal, laparoscopic, and robotic assisted laparoscopic approaches and InterStim implantation. This data will be utilized to evaluate the health benefits and outcomes of each of these procedures to enhance care and treatment.

Detailed Description
-----------------
The objective of this study is to initiate and maintain a patient information database that will be used to study the impact of each surgical procedure on patients' overall health, quality of life, and bowel/bladder/sexual function. The study coordinator will, on an ongoing basis, abstract needed medical information from inpatient hospital and physician office records for inclusion into the database.

Official Title
-----------------
Urology Database for Outcomes Research

Conditions
-----------------
Prostate Cancer, Pelvic Pain, Incontinence

Intervention / Treatment
-----------------
* Procedure: Radical Prostatectomy
* Procedure: InterStim Implantation
* Procedure: Pelvic organ prolapse repair


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients undergoing radical prostatectomy or InterStim implantation at William Beaumont Hospital. Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Radical Prostatectomy|Surgical procedure for prostate cancer.|
|Procedure: InterStim Implantation|surgical placement of the interstim|
|Procedure: Pelvic organ prolapse repair|Surgical pelvic organ prolapse repair|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prostate Cancer, Prostatectomy, Pelvic pain, urgency, incontinence, frequency
Effect of Training of Patients With Dysphagia

Study Overview
=================
Brief Summary
-----------------
Effect of training of patients with dysphagia

Detailed Description
-----------------
A randomised controlled study in the effect of training in patients with dysphagia. The patients are randomised for training or for usual care.

Official Title
-----------------
Effect of Training of Patients With Dysphagia

Conditions
-----------------
Dysphagia

Intervention / Treatment
-----------------
* Other: Chin Tuck Against Resistance


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with dysphaigia Patients living in the participating locations Exclusion Criteria: Patients who are linguistically or cognitively unable to participate Patients who are unable to collaborate about the training Palliative patients Patients with a probe

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Usual care<br>Usual care to patients with dysphagia | |
| Experimental: Training<br>Chin Tuck Against Resistance to patients with dysphagia | Other: Chin Tuck Against Resistance<br>* Training in 6 weeks 3 times a day.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Readmission | Number of readmissions within 6 months | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Quality of life | Level of quality of life - measured with Dysphagia Handicap Index questionnaire | 3 months | 
| Cost effectiveness | Economic evaluation of training compared to usual care, measured with EQ-5D | 6 months | 
| Mortality | Mortality in patients with dysphagia within 6 months | 6 months | 
| Swallowing function | Aspiration (yes/no) - measured with Volume Viscosity Swallow Test | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Training, Effect, Elderly
Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate)

Study Overview
=================
Brief Summary
-----------------
Multi-center, prospective randomized dosing and safety research study. A maximum of 150 men will be enrolled in the study. Qualifying patients will receive one of three possible doses of the study drug. Symptoms will be evaluated before treatment, and then 1-week, 1-month, 3-months, and 6-months following treatment.

Official Title
-----------------
Evaluation of the Safety and Tolerability of Transurethral Alcohol Injection for the Treatment of BPH (Enlarged Prostate)

Conditions
-----------------
Prostate Disease, BPH, Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy

Intervention / Treatment
-----------------
* Drug: dehydrated alcohol


Participation Criteria
=================
Eligibility Criteria
-----------------
Eligible patients are 50 to 80-year-old men who have experienced some or all of the following urinary symptoms for at least 6 months: frequent or urgent need to urinate difficulty starting their urinary stream interruption of their urinary stream feeling of incomplete emptying of bladder after urinating interruption of sleep due to the urge to urinate Patients should have tried oral medication for their condition in the past, and be willing to discontinue any current BPH medications for a period of time before undergoing study treatment. They should be in good general health and have no previous surgery, or other procedure(s) intended to reduce prostate size.

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: dehydrated alcohol|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
BPH, Prostate, Prostatitis
Hypotension in Children With Down Syndrome With Anesthesia Induction

Study Overview
=================
Brief Summary
-----------------
Children generally undergo induction of anesthesia by inhalation of sevoflurane. Children with Down Syndrome experience bradycardia with induction of anesthesia using sevoflurane. It is unknown if this bradycardia is isolate or results in hypotension, thus requiring treatment. Isolate bradycardia without hypotension does not require treatment and should be avoided as many of these patients have underlying cardiac anomalies.

Detailed Description
-----------------
Children generally undergo induction of anesthesia by inhalation of sevoflurane. This is particularly relevant for children with developmental delays as to avoid placement of an IV while awake. However, children with Down Syndrome experience bradycardia with induction of anesthesia using sevoflurane. It is unknown if this bradycardia is isolate or results in hypotension, thus requiring treatment. Isolate bradycardia without hypotension does not require treatment and should be avoided as many of these patients have underlying cardiac anomalies.

Official Title
-----------------
Incidence of Hypotension in Children With Down Syndrome During Induction of Anesthesia With Sevoflurane

Conditions
-----------------
Hypotension on Induction

Intervention / Treatment
-----------------
* Other: Non invasive blood pressure


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children <18 years old Requiring general anesthesia with inhalation induction Down syndrome ASA physical classification 1-3 Exclusion Criteria: Patients >18 years of age Patients without down syndrome Cyanotic congenital heart disease Use of antihypertensive medications Pulmonary hypertension patients undergoing intravenous induction of anesthesia ASA physical classification other than 1-3 emergency procedure

Ages Eligible for Study
-----------------
Minimum Age: 1 Week
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Trisomy 21 patients<br>Children <18 years old requiring general anesthesia with inhalation induction Down syndrome ASA physical classification 1-3 | Other: Non invasive blood pressure<br>* measurement of blood pressure during induction of general anesthesia<br>* Other names: blood pressure;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of non-invasive blood pressure during induction | non invasive blood pressure during induction (systolic, diastolic and Mean pressures) | 5 minutes |
Chart Review of Those Who Have Had Open, Laparoscopic, Ureteroscopic, or Percutaneous Surgery

Study Overview
=================
Brief Summary
-----------------
The investigator intends to review retrospective de-identified data of patients who have had Open, Laparoscopic, Ureteroscopic or Percutaneous Urologic Surgery.

Detailed Description
-----------------
The investigator reviews retrospective de-identified data of patients who have had Open, Laparoscopic, Ureteroscopic or Percutaneous Urologic Surgery in order to determine different clinical or operative issues.

Official Title
-----------------
Retrospective Chart Review of Patients Who Have Had an Open, Laparoscopic, Ureteroscopic or Percutaneous Surgery

Conditions
-----------------
Urologic Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients must have had Open, Laparoscopic, Ureteroscopic or Percutaneous Urologic Surgery at UCIMC Department of Urology

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Develop outcome effectiveness for minimally invasive procedures |  | December 2015 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Urologic Surgery